title: Chronic kidney disease induced dysfunction of high density lipoprotein.
abstract: Traditional risk factors do not account for increased cardiovascular disease in patients with chronic kidney disease (CKD), particularly individuals whose CKD has progressed to end-stage kidney disease requiring dialysis. CKD patients on dialysis show little to no cardiovascular benefits from lipid-lowering therapy and thus have an exaggerated residual cardiovascular risk. High density lipoprotein (HDL) quantity and functionality may explain some of the residual risk. CKD affects the composition and disrupts the functionality of HDL, including cholesterol acceptor function and inflammatory effects. Notably, although these HDL abnormalities prevail in CKD, they do not track together and thereby support the idea of separate and distinct mechanistic pathways for each critical function of HDL. Targeting individual perturbations in HDL function represents a novel approach to therapy in this population.
authors.affiliation: Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
authors.forename: Suguru
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Valentina
authors.initials: V
authors.lastname: Kon
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology*; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000503:physiopathology; D012307:Risk Factors
chemical_list: D008075:Lipoproteins, HDL
references.citation: N Engl J Med. 2009 Apr 2;360(14):1395-407
references.pmid: 19332456
references.citation: N Engl J Med. 2011 Jan 13;364(2):127-35
references.pmid: 21226578
references.citation: Immunity. 2013 Apr 18;38(4):754-68
references.pmid: 23477738
references.citation: J Am Soc Nephrol. 2011 Jul;22(7):1353-64
references.pmid: 21719791
references.citation: Arch Intern Med. 2004 Mar 22;164(6):659-63
references.pmid: 15037495
references.citation: Curr Opin Lipidol. 2012 Aug;23(4):353-66
references.pmid: 22732521
references.citation: Kidney Int. 2011 Jul;80(1):17-28
references.pmid: 21150873
references.citation: Arterioscler Thromb Vasc Biol. 2013 May;33(5):1020-7
references.pmid: 23493288
references.citation: N Engl J Med. 2005 Jul 21;353(3):238-48
references.pmid: 16034009
references.citation: Nat Rev Nephrol. 2011 May 31;7(7):385-97
references.pmid: 21629228
references.citation: N Engl J Med. 2004 Sep 23;351(13):1296-305
references.pmid: 15385656
references.citation: Atherosclerosis. 2012 Feb;220(2):493-501
references.pmid: 22119537
references.citation: J Nephrol. 2012 Mar-Apr;25(2):219-24
references.pmid: 21748719
references.citation: Lancet. 2013 Feb 16;381(9866):532-3
references.pmid: 23415297
references.citation: Curr Opin Cardiol. 2007 Jul;22(4):368-72
references.pmid: 17556891
references.citation: Lancet. 2012 Sep 1;380(9844):807-14
references.pmid: 22717317
references.citation: J Am Coll Cardiol. 2012 Dec 11;60(23):2372-9
references.pmid: 23141484
references.citation: Cardiovasc Res. 2012 Apr 1;94(1):154-62
references.pmid: 22328092
references.citation: J Am Soc Nephrol. 2011 Sep;22(9):1631-41
references.pmid: 21804091
references.citation: J Intern Med. 2006 Sep;260(3):231-7
references.pmid: 16918820
references.citation: Lancet. 2011 Jun 25;377(9784):2181-92
references.pmid: 21663949
references.citation: Am Heart J. 2013 Aug;166(2):373-380.e2
references.pmid: 23895822
references.citation: J Am Soc Nephrol. 2012 May;23(5):934-47
references.pmid: 22282592